← Leaderboards
Theodore M Kamenecka
Scripps Research Institute, The
$11,110,151
Attributed
$25,109,899
Total exposure
13
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,725,241 · 14
By mechanism
UH3$7,681,282 · 2
P01$7,281,190 · 2
R01$6,108,919 · 4
UG3$3,979,720 · 1
U01$3,330,990 · 1
R33$2,290,007 · 2
Top collaborators
- Patrick Robert Griffin16 shared
- Paul J Kenny13 shared
- Courtney A Miller13 shared
- Louis Daniel Scampavia8 shared
- Gavin R Rumbaugh6 shared
- Timothy Patrick Spicer4 shared
- Hugh Lee Sweeney4 shared
- Patricia Helen Mcdonald3 shared
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Barbara J Mason$35,175,467
- Jonathan Alan Hollander$446,034
- Patricia Helen McDonald$7,016,849
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPropertyDrug KineticsSmall MoleculeBrainReceptorIn VitroPharmaceutical ChemistryCellsDrug MetabolismDrug DiscoverySeriesResponseBasePenetrationStructure-Activity RelationshipSolubilityPharmaceutical PreparationsPharmacologyLeadDrug DevelopmentScaffoldLigandsReceptor Function
Grant awards (40)
Preclinical development of a precision therapy for a monogenic mental health disorder$1,806,486
U01 · FY2025 · MH
Preclinical development of a precision therapy for a monogenic mental health disorder$1,524,504
U01 · FY2024 · MH
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$475,793
R33 · FY2024 · NS
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$497,954
R33 · FY2023 · NS
Development of novel therapeutics for opioid dependence$1,972,485
UH3 · FY2022 · DA
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$229,400
R61 · FY2022 · NS
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$185,371
R61 · FY2022 · NS
Development of novel therapeutics for opioid dependence$1,972,485
UH3 · FY2021 · DA
Development of novel therapeutics for opioid dependence$1,972,485
UH3 · FY2020 · DA
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$731,424
R01 · FY2020 · MH · contact PI
Developing nonmuscle II inhibitors for substance use relapse$90,459
UH3 · FY2020 · NS
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$82,540
R01 · FY2020 · MH · contact PI
Development of novel therapeutics for opioid dependence$1,972,485
UG3 · FY2019 · DA
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$743,268
R01 · FY2019 · MH · contact PI
Developing nonmuscle II inhibitors for substance use relapse$180,291
UH3 · FY2019 · NS
Developing nonmuscle II inhibitors for substance use relapse$90,459
UH3 · FY2019 · NS
Development of novel therapeutics for opioid dependence$2,007,235
UG3 · FY2018 · DA
Developing nonmuscle II inhibitors for substance use relapse$631,712
UH3 · FY2018 · NS
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$598,887
R01 · FY2018 · MH · contact PI
Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer$439,200
R01 · FY2018 · CA
Optimization of ERRg-specific ligands as in vivo Chemical Probes$398,400
R01 · FY2018 · HD · contact PI
Developing nonmuscle II inhibitors for substance use relapse$148,694
UH3 · FY2018 · NS
Developing nonmuscle II inhibitors for substance use relapse$622,212
UH3 · FY2017 · NS
Development of RORbeta-selective modulators as in vivo probes$480,000
R01 · FY2017 · MH
Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer$439,200
R01 · FY2017 · CA
Optimization of ERRg-specific ligands as in vivo Chemical Probes$398,400
R01 · FY2017 · HD · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,652,504
P01 · FY2016 · DA · contact PI
Developing nonmuscle II inhibitors for substance use relapse$638,362
UH2 · FY2016 · NS
Development of RORbeta-selective modulators as in vivo probes$480,000
R01 · FY2016 · MH
Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer$439,200
R01 · FY2016 · CA
Optimization of ERRg-specific ligands as in vivo Chemical Probes$398,400
R01 · FY2016 · HD · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,652,935
P01 · FY2015 · DA · contact PI
Development of RORbeta-selective modulators as in vivo probes$480,000
R01 · FY2015 · MH
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,685,235
P01 · FY2014 · DA · contact PI
Development of Chemical Probes to Investigate the Role of NTSR1 in CNS Disorders$444,682
R33 · FY2014 · DA
Medicinal Chemistry$335,423
P01 · FY2014 · DA · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,624,668
P01 · FY2013 · DA · contact PI
Development of Chemical Probes to Investigate the Role of NTSR1 in CNS Disorders$426,896
R33 · FY2013 · DA
Medicinal Chemistry$330,425
P01 · FY2013 · DA · contact PI
Development of Chemical Probes to Investigate the Role of NTSR1 in CNS Disorders$444,682
R33 · FY2012 · DA